Motoric Cognitive Risk Syndrome in Polypharmacy.
Motoric Cognitive Risk Syndrome in Polypharmacy.
复制标题
DOI：
10.1111/jgs.16380
复制
发表时间：
2020-05
影响因子：
6.3
通讯作者：
Verghese J
中科院分区：
文献类型：
--
作者：
George CJ;Verghese J
运动认知风险综合征（MCR）是一种以步态缓慢和认知障碍为特征的痴呆前期综合征，其危险因素已经确定，但很少有可逆的。多种药物是认知能力下降的潜在可逆危险因素，但MCR和多种药物之间的关系尚未得到检验。我们的目的是比较MCR和多药的流行病学。横截面。基于社区的健康和退休研究队列。共1119例65岁及以上成人（平均年龄74.7±7.0岁，女性59%）。多重用药被定义为使用五种或五种以上的常规药物。MCR被定义为无痴呆个体的认知症状和步态缓慢。417名多药患者中MCR患病率为10%；在702名没有服用多种药物的参与者中，这一比例为6%。即使在对高危用药进行调整后，与不服用多种药物的患者相比，服用多种药物的患者符合MCR标准的几率为1.8（置信区间= 1.0-3.0;P = 0.035）。我们的研究结果显示，老年人中MCR和多药并存，提示痴呆的潜在可改变的危险因素。
Risk factors for motoric cognitive risk syndrome (MCR), a predementia syndrome characterized by slow gait and cognitive complaints, have been identified, but few are reversible. Polypharmacy is a potentially reversible risk factor for cognitive decline, but the relationship between MCR and polypharmacy has not been examined. Our aim was to compare the epidemiology of MCR and polypharmacy. Cross-sectional. Community-based Health and Retirement Study cohort. A total of 1119 adults 65 years and older (mean age = 74.7 ± 7.0 y; 59% female). Polypharmacy is defined as the use of five or more regularly scheduled medications. MCR is defined as cognitive complaints and slow gait in an individual without dementia. The prevalence of MCR among 417 participants with polypharmacy was 10%; it was 6% among 702 participants without polypharmacy. The odds of meeting MCR criteria in those with polypharmacy was 1.8 (confidence interval = 1.0–3.0; P = .035) compared with those without polypharmacy, even after adjusting for high-risk medication use. Our results show the coexistence of MCR and polypharmacy in older adults, suggesting a potentially modifiable risk factor for dementia.
登录
查看更多内容
DOI：
10.1016/j.jamda.2017.07.016
发表时间：
2018-01-01
影响因子：
7.6
作者：
Maguire, Fiachra J.;Killane, Isabelle;Reilly, Richard B.
通讯作者：
Reilly, Richard B.
影响因子：
5.3
作者：
Cheng, Chih-Ming;Chang, Wen-Han;Tsai, Chia-Fen
通讯作者：
Tsai, Chia-Fen
影响因子：
7
作者：
Martin, NJ;Stones, MJ;Bédard, M
通讯作者：
Bédard, M
影响因子：
9.8
作者：
Quinn KJ;Shah NH
通讯作者：
Shah NH
影响因子：
3.1
作者：
Maher RL;Hanlon J;Hajjar ER
通讯作者：
Hajjar ER